Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: CorMedix is a biopharmaceutical company focused on commercializing DefenCath, the first and only FDA-approved antimicrobial catheter lock solution in the U.S. DefenCath is indicated to reduce catheter-related bloodstream infections (CRBSI) in adult hemodialysis patients. The product launched commercially in April 2024 (inpatient) and July 2024 (outpatient). The company operates as a single segment in the United States.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $43,472 | $0 |
| Cost of Revenue | $(3,190) | $0 |
| Gross Profit | $40,282 | $0 |
| Operating Expenses | $(62,638) | $(48,958) |
| Net Loss | $(17,930) | $(46,339) |
| Cash and Cash Equivalents | $40,651 | $43,643 |
| Short-term Investments | $11,037 | $32,388 |
| Total Liquidity (Cash + ST Inv) | $51,688 | $76,031 |
| Accumulated Deficit | $(339,630) | $(321,700) |
Quarterly Performance (2024): The company achieved profitability in Q4 2024 with revenue of $31.2 million and net income of $12.9 million, driven by strong product sales. Q1-Q3 2024 remained loss-making.
Material Changes vs. Prior Period
- Revenue Generation: Revenue increased from $0 in 2023 to $43.5 million in 2024 following the commercial launch of DefenCath. Q4 2024 alone accounted for $31.2 million of this total.
- Net Loss Reduction: Net loss decreased by 61% to $17.9 million from $46.3 million in 2023, primarily due to revenue recognition and a $1.4 million tax benefit from the sale of New Jersey net operating losses (NOLs).
- Expense Shifts:
- R&D: Decreased 70% to $3.9 million as costs shifted from development to commercialization.
- Selling & Marketing: Increased 59% to $28.7 million to support the sales force and launch.
- G&A: Increased 69% to $30.0 million due to personnel and compliance costs associated with commercial operations.
- Balance Sheet: Trade receivables increased by $51.8 million to $51.7 million, and inventory increased by $5.5 million to $7.6 million to support sales.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management estimates sufficient cash, cash equivalents, and short-term investments ($51.7 million) to fund operations for at least twelve months from the filing date. The company has $30.2 million remaining capacity under its At-The-Market (ATM) program and $100 million under its 2024 Shelf Registration Statement.
Reimbursement Status:
- Inpatient: New Technology Add-On Payment (NTAP) approved by CMS, providing reimbursement of 75% of WAC per vial.
- Outpatient: Transitional Drug Add-On Payment Adjustment (TDAPA) approved for 100% ASP reimbursement starting July 1, 2024. Pass-through status under OPPS also secured for ambulatory settings.
Key Risks and Contingencies:
- Customer Concentration: One customer accounted for 86% of total revenue in 2024. Two customers accounted for 99% of accounts receivable.
- Legal Proceedings: The company is defending against consolidated securities class action litigation and shareholder derivative litigation regarding prior disclosures related to DefenCath's NDA submission and manufacturing. Management intends to vigorously contest these claims.
- Supply Chain: Reliance on single-source suppliers for key active pharmaceutical ingredients (APIs) and third-party contract manufacturers.
- Patent Exclusivity: DefenCath holds New Chemical Entity (NCE) exclusivity until 2028 and GAIN Act exclusivity until 2033.
Investor Verification Checklist
- Customer Concentration Risk: Verify the stability of the single customer representing 86% of revenue and the potential impact of contract changes.
- Reimbursement Sustainability: Monitor CMS policy changes regarding NTAP and TDAPA, as these temporary add-on payments are critical to current margins.
- Liquidity Runway: Confirm the burn rate relative to the $51.7 million cash position and the necessity of future capital raises (ATM or equity offerings).
- Legal Exposure: Track the status of the securities class action and derivative litigation for potential settlement costs or injunctions.
- Supply Chain Resilience: Assess progress in qualifying alternate suppliers for heparin sodium API to mitigate single-source risk.